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Abstract
Objective
Subependymal Giant Cell Astrocytomas (SEGAs) are slow-growing 
glioneuronal tumors typically found around the ventricles of the brain, 
particularly near the foramen of Monro in 15%-20% of patients with 
tuberous sclerosis complex (TSC). Surgical resection is the standard 
treatment for these symptomatic tumors. The mTOR inhibitor 
everolimus can be regarded as an alternative treatment for SEGAs 
due to the complications of surgery.  The present study primarily 
aimed to specify the effect of everolimus on SEGA volume change 
before and after treatment. The secondary objective was to determine 
the effect of this drug on renal angiomyolipoma (AML), skin lesions, 
and seizures in TSC patients.  
Materials & Methods
This pre- and post-treatment clinical trial was performed on 14 
children (eight females and six males with a mean age of 10 years) 
previously diagnosed with TSC based on the diagnostic criteria. The 
subjects received oral everolimus at a dose of 3 mg/m2 for at least six 
months. 
Results
Half of the patients had more than 30% of volume loss in SEGA, and 
in 28.5% of them, a ≥ 50% reduction in SEGA volume was observed 
(P=0.01). Moreover, 92.9% of the patients had a ≥ 50% decrease in 
the frequency of seizures (P=0.000). The response rate in AML and 
skin lesions was 14.2% and 50%, respectively.   
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Introduction
Tuberous sclerosis, a genetic disorder with 
autosomal dominant inheritance, occurs in 
approximately 1/5800 live births (1). This disease 
is currently known as tuberous sclerosis complex 
(TSC) due to its probable effects on one or 
several other vital organs in addition to the central 
nervous system. This condition is characterized 
by the presence of hamartomas in many organs, 
especially the brain (such as cortical tubers, 
subependymal giant cell astrocytomas (SEGAs), 
and subependymal nodules), eyes, kidneys, skin, 
and heart (2, 3). 
Its clinical manifestations vary from mild cases with 
exclusive affection of the skin to life-threatening 
complications, such as hydrocephalous. The 
involvement of different organs is dependent on 
age; for instance, cardiac lesions usually occur in 
younger individuals, even in the fetal period, and 
renal lesions are often detected after adolescence. 
About one million people are affected by this 
disorder around the world (4). 
Neurologic manifestations in TSC patients range 
from normal intelligence and the absence of 
seizures to intellectual disability and drug-resistant 
epilepsy. With a prevalence of 80-90%, the seizure 
is the most common neurologic sign in these 
patients (5-7). In these people, the seizure is mostly 
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treatment for symptomatic SEGA in TSC patients.
Keywords: Everolimus; Subependymal Giant Cell Astrocytoma; 
Tuberous Sclerosis Complex
DOI: 10.22037/ijcn.v15i4.30591
drug-resistant, and its control is significantly 
correlated with the cognitive performance of the 
patients (7, 8). There is no simple and easy test for 
TSC diagnosis. Although genetic studies have been 
proposed for this disease, diagnosis is currently 
based on clinical symptoms and paraclinical 
findings, and treatment depends on the signs (2).   
The major pathogenesis of tuberous sclerosis 
is the existence of tumor-like lesions (such as 
hamartomas) in diverse body organs, developed as 
a result of the mutation in either TSC 1 or TSC2 
(9). Subependymal Giant Cell Astrocytomas 
(SEGAs) are slow-growing glioneuronal tumors 
typically found around the ventricles of the brain, 
particularly near the foramen of Monro in 15%-
20% of the patients with TSC (3). The growth of 
this tumor is accompanied by a disturbed flow of 
cerebrospinal fluid, ensuing headache, vomiting, 
behavioral disorders, decreased sight, and sudden 
death from fatal acute hydrocephalous, and its risk 
is directly proportional to SEGA volume. These 
lesions do not regress spontaneously, but their 
volume increases progressively (2, 4, 10).     
Although surgery is the standard treatment for 
SEGA (5), complete resection is difficult due to 
the depth of these lesions along with the serious 
complications. Furthermore, tumor residues might 
lead to growth and relapse (10). Complete tumor 
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resection was achieved in 66% of the patients, 
relapse was observed in 34% of the cases a year 
following the operation, and sequels of surgery 
occurred in 49% of the subjects (4). Consequently, 
it is only logical to evaluate effective non-surgical 
treatments. 
Recent studies (11, 12) have indicated the impact 
of the mammalian target of rapamycin (mTOR) 
inhibitor on SEGA regression in TSC patients. 
Based on the results of these studies, the Food 
and Drug Administration (FDA) has approved the 
application of this agent in TSC patients who are 
not suitable candidates for surgical resection (13). 
This approval has entailed the expansive usage 
of this medicine, and there is even consensus 
concerning the application of mTOR in patients 
with growing SEGA and no clinical signs. 
Everolimus is a rapamycin analog that reduces 
tumor volume through inhibiting mTOR in TSC 
patients (10). The present study primarily was done 
to specify the effect of mTOR on SEGA volume 
change before and after treatment. The secondary 
objective of this study was to determine the effect 
of this drug on renal angiomyolipoma (AML), skin 
lesions, and seizures in TSC patients. 
To our knowledge, there is no comprehensive data 
regarding the safety and efficacy of this drug in 
TSC children in Iran. 
Materials & Methods
This prospective open-label, pre-, and post-
treatment clinical trial was conducted on 17 
patients previously diagnosed with TSC according 
to the diagnostic criteria in clinical and paraclinical 
evaluations. Via convenience sampling method, 
the participants were selected from those who were 
referred to the Children Neurology Clinic in the 
Pediatric Hospital of Tabriz affiliated with Tabriz 
University of Medical Sciences from August 2017 
to March 2019. The inclusion criteria were at least 
one SEGA lesion larger than 0.5 cm in Magnetic 
Resonance Imaging (MRI) of the brain and 
willingness to enter the study.
The age range of the subjects was 3-19 years, with 
a mean age of 10 years. The paraclinical tests, 
including complete blood count (CBC), differential 
count, and biochemical tests for liver function tests, 
renal function, and lipid profile were performed at 
the beginning and six months after the treatment 
at the same center. Following initial assessments, 
Everolimus (Afinitor, Novartis) was prescribed at 
a dose of 3 mg/m2. Drug titration and blood level 
measurement were not possible. The patients were 
visited by the same pediatric neurologist monthly 
and examined in terms of medication side effects 
and drug efficacy. 
Brain lesions were assessed by MRI at a power of 
1.5 teslas at the beginning and six months post-
treatment with the same apparatus and reported by 
the same radiologist. The largest lesion diameter 
was measured using T1 VIBE fat-saturated images 
in axial, sagittal, and coronal slices. Afterward, the 
volume was calculated as follows: length × width 
× height/2. 
In some studies, a reduction of 30% or more and 
no new lesions during treatment were considered 
as the criteria for positive medication effects (14). 
However, in most studies, at least a 50% decrease 
was regarded for the positive effect of the drug on 
SEGA. In this study, we considered a reduction of ≥ 
30% as a relative response and ≥ 50% as a favorable 
response. Seizure frequency was specified by 
a pediatric neurologist according to the clinical 
history and EEG at the beginning and six months 
after the treatment. During the observation period, 
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AEDs remained unchanged, and everolimus was 
used as adjunctive, and baseline seizure frequency 
was assessed. A decrease of 50% or more in the 
frequency of seizures was considered favorable for 
this medicine. 
In renal AML, a reduction of 50% or more relative 
to AML volume in the baseline in the absence of 
new AML ≥1 cm and no AML-related bleeding of 
grade ≥ 2 was considered as a positive effect.
This study was approved by the Ethics 
Committee of Tabriz University of Medical 
Sciences (IR.TBZMED.REC.1396.287 & 
IRCT20131012014988N2). Prior to treatment 
with Everolimus, informed consent was obtained 
from both parents and patients (when possible).  
Data were analyzed using SPSS software version 
21. The normality of data distribution was assessed 
by the Kolmogorov-Smirnov test. The qualitative, 
normal quantitative, and non-normal quantitative 
variables were described by frequency (percentage), 
mean (standard deviation), and median (25 and 75 
percentile), respectively. To analyze the pre- and 
post-treatment data, McNemar’s test was applied 
for the qualitative two-level variables, and the Sign 
test was utilized for the ordinal factors. A P < 0.05 
was considered as the significance level for all 
tests. 
Results
We evaluated 17 patients with SEGA in the present 
study. The treatment was ceased in one of the 
patients due to severe oral aphthous ulcers, and 
two patients left the study three months after its 
initiation. Ultimately, 14 patients (eight females 
and six males) were enrolled in this study for at 
least six months. Table 1 presents the baseline 
demographic data and the clinical findings of the 
TSC patients of different ages.
The mean age of the subjects was 10±3.3 years. 
All subjects had SEGA at baseline, and 71.4% 
had renal AML. Concerning other criteria, all 
patients had at least one skin lesion, 28.6% had 
retinal involvement, and cardiac involvement was 
observed in 35.5% of the patients.
In three patients (21.4 %), SEGA volume loss 
of 30% to less than 50% was noted; however, a 
reduction rate of 50% or more in SEGA volume 
was observed in 4 out of 14 (28.5%) patients 
(Fig.1). SEGA progression was detected in one 
patient (Case # 2, Table 1). The decrease in SEGA 
volume was statistically significant (P<0.01).
The medication was observed to be effective in 
seizure control. More specifically, the seizure was 
reduced by 90% and 50%-90% in 10 and three 
cases, respectively (P <0.001) (Table 2).
Out of 14 patients, 10 cases had AML at baseline, 
and only two patients (14.3%) responded to 
everolimus at 3 mg/m2.
All 14 patients had at least one skin lesion. 
Angiofibroma and hypomelanotic lesions were 
detected in 92.9% and 100% of the patients, 
respectively. Approximately half of the patients 
responded to the treatment. Facial angiofibromas 
decreased in size and became paler and less rough 
in 42.9% of the patients, but the number of lesions 
remained unchanged. The hypomelanotic macules 
regressed in size and color in half the patients, and 
no worsening of lesions was found during this 
study.
Although we did investigate the influence of 
this medication on the cognitive and behavioral 
performance of the patients, most parents 
were satisfied with the enhanced cognitive and 
behavioral performance of their children.  
Medication Side Effects: Symptoms of upper 
respiratory infection and pharyngitis were found in 
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three patients; upon the emergence of these signs, 
the treatment was stopped and resumed after their 
resolution. However, one subject exhibited serious 
oral aphthous lesions and was excluded from the 
study. By stopping the drug, oral aphthous was 
resolved. 
Table 1. Baseline demographic and clinical findings of the enrolled patients
Pt.nr./
gender
Age at drug 
start
Epilepsy SEGA SEN Hypopigmented 
macules
Angiofibroma AML Cardiac 
lesions
1/M 19 Yes Yes Yes Yes Yes Yes No
2/F 13 Yes Yes No Yes Yes Yes No
3/F 8 Yes Yes Yes Yes Yes Yes Yes
4/M 10 Yes Yes Yes Yes No Yes No
5/F 14 Yes Yes Yes Yes Yes Yes No
6/F 8 Yes Yes Yes Yes Yes No No
7/F 10 Yes Yes Yes Yes Yes No No
8/M 7 Yes Yes Yes Yes Yes Yes Yes
9/M 10 Yes Yes Yes Yes Yes Yes No
10/M 9 Yes Yes Yes Yes Yes No No
11/F 10 Yes Yes Yes Yes Yes Yes Yes
12/F 6 Yes Yes Yes Yes Yes Yes Yes
13/M 9 Yes Yes Yes Yes Yes No No
14/F 7 Yes Yes Yes Yes Yes Yes Yes
AML, Angiomyolipoma ; F, Female ; M, Male ; mo,months ; nr., Number ; Pt., Patient ; SEGA, Subependymal 
Giant Cell Astrocytoma ; SEN, Sub Ependymal Nodules.
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The objective of this study was to evaluate the 
efficacy and safety of everolimus at a dose of 3 
mg/m2 in patients with TSC. Because we were not 
able to monitor the drug blood level, the treatment 
was commenced with a low drug dose. Meanwhile, 
after six months or more, the everolimus treatment 
resulted in a significant reduction in TSC symptoms 
and side effects.
Using the evaluated dose of everolimus, the SEGA 
response rate was 28.5%, and 21.4% of the patients 
showed noticeably reduced SEGA volumes. 
However, SEGA progression was detected in 
one patient who was a 13-year-old girl. SEGA 
progression rate was low (7.1%) in this study, 
which is in line with several studies, such as that 
of Trelinska et al. on 10 patients with TSC-related 
SEGA. They concluded that maintenance therapy 
with everolimus was an effective treatment method, 
which balanced the side effects for patients with 
TSC and SEGA following the standard treatment 
(10).  
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Franz et al. (15) reported that everolimus 
significantly decreased the SEGA volume. Besides, 
Fogarasi et al. (16) confirmed the impact of 
Everolimus in SEGA treatment. In another study, 
titled “Everolimus for SEGA: Final five-year 
Analysis”, Franz et al. (17) revealed that everolimus 
imposed a stable impact on SEGA tumor reduction 
after more than five years of treatment. 
In 2017, Arroyo et al. (18) conducted a study 
on a seven-year-old boy who had a large SEGA 
mass and immediately received everolimus. They 
reported that everolimus effectively reduced the 
tumor volume without the need for surgery. All 
the foregoing studies confirm the influence of 
everolimus on the treatment of SEGA caused by 
TSC. 
The present study mainly aimed at examining the 
effect of everolimus on SEGA, but we further 
evaluated the drug effect on other organs inflicted 
by TSC. A slight effect on renal angiomyolipoma 
and positive results associated with skin lesions 
were observed. The low response rate of renal 
angiomyolipoma might be attributed to the low 
drug dose and shortness of treatment. In most 
studies, treatment continued for more than 24 
months. In the study carried out by Franz et al., the 
response rate was 54% after an average treatment 
duration of 28.9 months (19).
Based on the present study, in 42.9% of the patients, 
facial angiofibromas decreased in size and became 
paler and less rough. Also, the hypomelanotic 
macules regressed in size and color in 50% of 
the patients. Cie et al. demonstrated a skin lesion 
response rate of 37.5% after 12 months of therapy 
at a dose of 4.5 mg/m2 (20). Franz et al. observed 
a skin lesion response rate of 58.1% at 4.5 mg/m2 
dose (21). Seemingly, skin lesion also responds to 
low doses of everolimus.
In TSC patients, the seizure is one of the most 
prevalent manifestations, usually occurring as 
infantile spasm during infancy (22). In this study, 
Everolimus significantly lowered seizure frequency 
in TSC patients. Many studies are consistent with 
the present research, confirming the efficacy of 
everolimus in reducing seizure frequency in TSC 
patients (8, 23-31).
Mizuguchi et al. (32) and Hwang et al. (33) 
observed notable improvement in behavior and 
autistic symptoms in patients but we did not control 
it by questionnaire.
Limitations of this study
No genetic studies for mutations of TSC1 and 
TSC2, small sample size, and short follow-up due 
to high cost of the drug, no checking for drug level 
due to unavailability to do in our center. 
In Conclusion 
According to the findings of this study, 
everolimus significantly affected the multisystem 
manifestation of TSC. More specifically, this drug 
reduced the seizure frequency and SEGA volume 
in TSC patients, which can be a safe alternative 
treatment for TSC patients with SEGA. 
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